Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease.
The American journal of cardiology, 1997•europepmc.org
… This randomized, double-blind, placebo-controlled study shows that 20-week fluvastatin
treatment induces beneficial changes in the lipid panel and a shift in the fibrinolytic pathway
toward activation through a decrease in tissue plasminogen activator antigen. Fluvastatin
treatment causes no variation in lipoprotein(a) circulating levels. … The role of HMG-CoA
reductase inhibitors in the treatment of hyperlipidemia: a review of fluvastatin …
treatment induces beneficial changes in the lipid panel and a shift in the fibrinolytic pathway
toward activation through a decrease in tissue plasminogen activator antigen. Fluvastatin
treatment causes no variation in lipoprotein(a) circulating levels. … The role of HMG-CoA
reductase inhibitors in the treatment of hyperlipidemia: a review of fluvastatin …
A comment on this article appears in" Another view of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and the fibrinolytic system." Am J Cardiol. 1997 Oct 1; 80 (7): 977-8. A comment on this article appears in"" Am J Cardiol. 1997 Oct 1; 80 (7): 977-8.
europepmc.org
以上显示的是最相近的搜索结果。 查看全部搜索结果